2026-01-27 - Analysis Report
**Company Overview:** Eli Lilly is a leading American pharmaceutical company that develops and manufactures human and animal medicines.

**Return Rate Analysis:**

* Cumulative return of review stock (LLY): 660.89%
* Cumulative return of comparison stock (S&P 500, VOO): 127.58%
* Divergence (max: 577.90, min: -22.40, current: 535.60, relative divergence: 93.00%)

Based on the cumulative returns, the review stock (LLY) has significantly outperformed the comparison stock (VOO) with a divergence of 535.60. This indicates a high level of volatility and potential for future growth.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 46.0% | 14.2% | 38.0% | 0.7 | 103.7B |
| 2017-2019  | 54.0% | 12.1% | 29.0% | 0.7 | 117.8B |
| 2018-2020  | 82.0% | 19.7% | 58.0% | 0.7 | 151.4B |
| 2019-2021  | 128.0% | 19.7% | 64.0% | 0.7 | 247.6B |
| 2020-2022  | 169.0% | 19.7% | 165.0% | 0.7 | 328.0B |
| 2021-2023  | 259.0% | 18.2% | 241.0% | 0.5 | 522.6B |
| 2022-2024  | 349.0% | 23.9% | 320.0% | 0.6 | 692.1B |
| 2023-2025  | 454.0% | 33.4% | 378.0% | 0.7 | 963.4B |

The review stock (LLY) has consistently demonstrated high CAGR and Alpha values, indicating strong long-term growth potential. The Beta values range from 0.5 to 0.7, indicating moderate volatility.

**Recent Stock Price Fluctuations:**

* Close: $1,062.75
* 5-day SMA: $1,066.85
* 20-day SMA: $1,069.54
* 60-day SMA: $1,029.54

The review stock has experienced a slight decline in recent days, with the 5-day SMA slightly above and the 20-day SMA significantly above the current price.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**

* Market Risk Indicator (MRI): 0.70
* RSI: 54.15
* PPO: -0.28
* Hybrid Signal: Buy (Cash 0%)

The review stock's RSI is currently at a neutral level. The PPO is in a negative range, indicating potential selling signals. The MRI indicates a medium investment risk.

**Recent News & Significant Events:**

[2026-01-23] Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance (news.google.com)
[2026-01-26] FDA Delays Lillyâ€™s Weight-Loss Pill: Is the Stock Still a Buy for 2026? - NAI500 (news.google.com)
[2026-01-16] Buy The Dip In LLY Stock? - Forbes (news.google.com)
[2026-01-26] Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? - The Motley Fool (news.google.com)
[2026-01-21] Eli Lilly: Buy Ahead Of Its Earnings Day (Preview) (NYSE:LLY) - Seeking Alpha (news.google.com)
[2026-01-26] Eli Lilly and Company $LLY Shares Sold by OneAscent Financial Services LLC - MarketBeat (news.google.com)

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 28
- Target Price (avg/high/low): 1112.68 / 1500.00 / 770.00

Analysts have a consensus "Buy" rating with a slightly bullish target price.

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |

The review stock has demonstrated healthy earnings with a steady increase in EPS and Revenue.

**Financial Information - Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

The review stock has consistently demonstrated high revenue and profit margins.

**Financial Information - Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

The review stock has demonstrated healthy equity and ROE values.

**Comprehensive Analysis:**

Based on the analysis, the review stock (LLY) has demonstrated strong long-term growth potential with high CAGR and Alpha values. The current market risk indicator (MRI) indicates a medium investment risk. However, the review stock's RSI and PPO indexes are neutral and negative, respectively, indicating potential selling signals. The analyst consensus is "Buy" with a slightly bullish target price. Overall, the review stock has healthy earnings and revenue with consistent profit margins and a strong equity position.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.